Campiglio M - Search Results

1

Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.

De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino F, Pratesi G, Tagliabue E, Balsari A. De Cesare M, et al. Among authors: campiglio m. J Immunother. 2010 Jan;33(1):8-15. doi: 10.1097/CJI.0b013e3181affaa7. J Immunother. 2010. PMID: 19952960

2

Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L. Le Noci V, et al. Among authors: campiglio m. Oncoimmunology. 2016 Sep 20;5(11):e1234571. doi: 10.1080/2162402X.2016.1234571. eCollection 2016. Oncoimmunology. 2016. PMID: 27999750 Free PMC article.

3

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.

Rybinska I, Sandri M, Bianchi F, Orlandi R, De Cecco L, Gasparini P, Campiglio M, Paolini B, Sfondrini L, Tagliabue E, Triulzi T. Rybinska I, et al. Among authors: campiglio m. Cells. 2020 Feb 13;9(2):434. doi: 10.3390/cells9020434. Cells. 2020. PMID: 32069815 Free PMC article.

4

Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.

Bianchi F, Tagliabue E, Ménard S, Campiglio M. Bianchi F, et al. Among authors: campiglio m. Cell Cycle. 2007 Mar 15;6(6):643-6. doi: 10.4161/cc.6.6.4033. Epub 2007 Mar 20. Cell Cycle. 2007. PMID: 17374991 Free article. Review.

5

HER2 as a target for breast cancer therapy.

Tagliabue E, Balsari A, Campiglio M, Pupa SM. Tagliabue E, et al. Among authors: campiglio m. Expert Opin Biol Ther. 2010 May;10(5):711-24. doi: 10.1517/14712591003689972. Expert Opin Biol Ther. 2010. PMID: 20214497 Review.

6

Activity and resistance of trastuzumab according to different clinical settings.

Tagliabue E, Campiglio M, Pupa SM, Ménard S, Balsari A. Tagliabue E, et al. Among authors: campiglio m. Cancer Treat Rev. 2012 May;38(3):212-7. doi: 10.1016/j.ctrv.2011.06.002. Epub 2011 Jul 2. Cancer Treat Rev. 2012. PMID: 21726959 Review.

7

"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.

Tagliabue E, Campiglio M. Tagliabue E, et al. Among authors: campiglio m. Front Oncol. 2014 Nov 18;4:334. doi: 10.3389/fonc.2014.00334. eCollection 2014. Front Oncol. 2014. PMID: 25478327 Free PMC article. No abstract available.

8

The HER2 World: Better Treatment Selection for Better Outcome.

Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Tagliabue E, et al. Among authors: campiglio m. J Natl Cancer Inst Monogr. 2011;2011(43):82-5. doi: 10.1093/jncimonographs/lgr041. J Natl Cancer Inst Monogr. 2011. PMID: 22043048

9

Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.

Bianchi F, Sasso M, Turdo F, Beretta GL, Casalini P, Ghirelli C, Sfondrini L, Ménard S, Tagliabue E, Campiglio M. Bianchi F, et al. Among authors: campiglio m. J Cell Physiol. 2015 Nov;230(11):2661-70. doi: 10.1002/jcp.24968. J Cell Physiol. 2015. PMID: 25711523

10

Biologic and therapeutic role of HER2 in cancer.

Ménard S, Pupa SM, Campiglio M, Tagliabue E. Ménard S, et al. Among authors: campiglio m. Oncogene. 2003 Sep 29;22(42):6570-8. doi: 10.1038/sj.onc.1206779. Oncogene. 2003. PMID: 14528282 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters